Inhibiting a previously undruggable protein holds promise for treatment of numerous types of cancer.
Blocking a specific protein linked with cancer growth may lead to the development of a breakthrough new class of oncology drugs, a recent study found.
The study, published in the current issue of ACS Chemical Biology, evaluated 6 chemical compounds that inhibit the so-called “oncoprotein” HuR, which binds to RNA and promotes tumor growth.
"These are the first reported small-molecule HuR inhibitors that competitively disrupt HuR-RNA binding and release the RNA, thus blocking HuR function as a tumor-promoting protein," corresponding author Liang Xu said in a press release.
Read more at Specialty Pharmacy TImes: http://bit.ly/1aUR8oP